Compare BLDR & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLDR | ASND |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 13.6B |
| IPO Year | 2005 | 2014 |
| Metric | BLDR | ASND |
|---|---|---|
| Price | $85.66 | $243.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 16 |
| Target Price | $128.44 | ★ $279.50 |
| AVG Volume (30 Days) | ★ 2.0M | 458.1K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $15,190,638,000.00 | N/A |
| Revenue This Year | $0.88 | $97.60 |
| Revenue Next Year | $4.64 | $43.64 |
| P/E Ratio | $21.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $76.50 | $150.99 |
| 52 Week High | $151.03 | $248.60 |
| Indicator | BLDR | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 63.42 |
| Support Level | $80.00 | $190.49 |
| Resistance Level | $130.47 | $248.60 |
| Average True Range (ATR) | 3.85 | 9.37 |
| MACD | 1.17 | 1.74 |
| Stochastic Oscillator | 86.46 | 90.75 |
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.